RxDoctor Payments Data

Galina Bendich, MD

Internal Medicine · Bronx, NYNPI 1376590596

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 35.9% of the total.

$692in general payments, 2019–2025

Across 32 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$249
  • Novo Nordisk$157
  • GSK$123
  • Lilly USA, LLC$76
  • Exact Sciences$64
  • Amgen$23

What the payments were for

  • Food & beverage$692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie12$249
Novo Nordisk8$157
GSK5$123
Lilly USA, LLC3$76
Exact Sciences3$64
Amgen1$23

How this compares

$692 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$15,342
Medicare patients
27
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin115$87,813
JanuviaSitagliptin Phosphate81$50,611
TrulicityDulaglutide28$29,482
JanumetSitagliptin Phos/Metformin Hcl40$25,958
EliquisApixaban40$23,878
TradjentaLinagliptin23$18,122
EntrestoSacubitril/Valsartan16$15,726
Diclofenac Sodium107$12,333
XareltoRivaroxaban17$9,035
Albuterol Sulfate HfaAlbuterol Sulfate268$8,829
Breo ElliptaFluticasone/Vilanterol20$7,748
FarxigaDapagliflozin Propanediol13$7,194
Advair HfaFluticasone Propion/Salmeterol20$6,541
Tresiba Flextouch U-100Insulin Degludec15$6,185
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$4,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$76$29,48228 claims
GSKBreo Ellipta$123$7,74820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →